Salarius SLRX officer reports Series A preferred and option grants

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. (SLRX) filed an initial Form 3 for its Chief Scientific Officer, reporting only derivative securities. The reporting person holds Series A Preferred Stock that is convertible into 141,734 shares of common stock. The Series A Preferred has no expiration date and will convert automatically into common shares after stockholder approval and satisfaction of specified Nasdaq listing standards.

The filing also reports two stock options for common stock: one covering 5,061 shares with an exercise price of $4.9369 per share and another covering 8,318 shares with an exercise price of $50.2579 per share. Both option grants become exercisable only after stockholder approval and satisfaction of certain Nasdaq listing standards, so their potential value depends on these conditions being met.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Hibner Barbara Louise

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
holding	Series A Preferred Stock	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Series A Preferred Stock — 50.619 shares (Direct); Stock Option (right to buy) — 5,061 shares (Direct)

Footnotes (1)

1. The Series A Preferred Shares are convertible into 141,734 shares of Common Stock. The Series A Preferred Shares have no expiration date, and convert automatically into shares of Common Stock following stockholder approval and satisfaction of certain Nasdaq listing standards. The Stock Options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hibner Barbara Louise

(Last) (First) (Middle)

2450 HOLCOMBE BLVD STE X

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/12/2025

3. Issuer Name and Ticker or Trading Symbol
Salarius Pharmaceuticals, Inc. [ SLRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	(1)	Common Stock	50.619	(1)	D
Stock Option (right to buy)	(2)	03/31/2032	Common Stock	5,061	$4.9369	D
Stock Option (right to buy)	(2)	07/15/2030	Common Stock	8,318	$50.2579	D

Explanation of Responses:

1. The Series A Preferred Shares are convertible into 141,734 shares of Common Stock. The Series A Preferred Shares have no expiration date, and convert automatically into shares of Common Stock following stockholder approval and satisfaction of certain Nasdaq listing standards.

2. The Stock Options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Remarks:

Exhibit 24, Power of Attorney, is attached.

	/s/Mark Rosenblum, as Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Salarius Pharmaceuticals (SLRX) Form 3 filing disclose?

The Form 3 discloses the initial beneficial ownership of derivative securities held by Salarius Pharmaceuticals' Chief Scientific Officer, including Series A Preferred Stock and stock options tied to common shares.

How many Salarius (SLRX) common shares are tied to the Series A Preferred Stock?

The filing states that the Series A Preferred Shares are convertible into 141,734 shares of common stock with no expiration date, subject to stockholder approval and certain Nasdaq listing standards.

What stock options are reported in this Salarius SLRX Form 3?

Two stock options are reported: one for 5,061 common shares with an exercise price of $4.9369 per share expiring on 03/31/2032, and another for 8,318 common shares with an exercise price of $50.2579 per share expiring on 07/15/2030.

When do the Salarius (SLRX) stock options and preferred stock become exercisable or convertible?

Both the Series A Preferred Shares and the reported stock options become convertible or exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Does this Salarius Pharmaceuticals Form 3 involve any non-derivative common stock?

Table I for non-derivative securities shows no entries in the provided excerpt, and the ownership reported consists of derivative securities only.

Who is the reporting person in the Salarius (SLRX) Form 3 filing?

The reporting person is identified as an officer of Salarius Pharmaceuticals, Inc., serving as the company's Chief Scientific Officer, filing individually on this Form 3.